Vitamin D Supplementation Improves Cognitive Function Through Reducing Oxidative Stress Regulated by Telomere Length in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized Controlled Trial.

Plain-language guide to PMID 33164936 (2020): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 183 subjects.

Key Facts

PMID: 33164936
Journal: Journal of Alzheimer's disease : JAD
Year: 2020
Study type: Randomized Controlled Trial
Authors: Yang T et al. (7 authors)
DOI: 10.3233/JAD-200926

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Cognitive decline in older adults is a serious public health problem today.

Association between vitamin D supplementation and cognition remains controversial.

Who Took Part

The study group was 183 subjects.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the subjects nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

This was a double-blind, randomized, placebo-controlled trial in Tianjin, China.

Tests of cognitive function and mechanism-related biomarkers were evaluated at baseline, 6 months, and 12 months.

What Was Measured

PubMed files the paper under topics including 8-Hydroxy-2'-Deoxyguanosine, Calcifediol, Calcitriol, Cholecalciferol, Cognition, Cognitive Dysfunction and Cyclin-Dependent Kinase Inhibitor p16.

The authors tagged it with the keywords Cognitive performance, oxidative stress, telomere and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 183 subjects.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Journal of Alzheimer's disease : JAD), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.